KPV Prices

KPV is a tripeptide (Lys-Pro-Val, MW ≈ 342.4 g/mol, CAS 67727-97-3) corresponding to the C-terminal positions 11-13 of alpha-melanocyte-stimulating hormone (α-MSH), it keeps the parent hormone's anti-inflammatory activity but not its pigmentation effects.

Its primary action is inhibition of NF-κB, a master transcription factor for inflammatory genes, which suppresses pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) at nanomolar concentrations.

It does NOT bind melanocortin receptors and does not raise cAMP; instead, in the gut it depends on the PepT1 di/tripeptide transporter for cellular uptake, so it is preferentially taken up by inflamed intestinal tissue, where PepT1 is overexpressed.

It is NOT FDA-approved; the entire evidence base is preclinical (cell culture + animal models of IBD, colitis-associated cancer, dermatitis, and bronchial inflammation), no completed human clinical trials exist.

Regulatory status is in flux: KPV was on the FDA's Category 2 bulk-substances list, and a February 2026 HHS announcement proposed reclassifying ~14 peptides including KPV back to Category 1 (compoundable with a prescription), but the formal updated list had not been published as of writing.

PeptidePrices safety rating

7/10 · Not FDA-approved

Mechanism

C-terminal tripeptide of alpha-MSH; binds melanocortin receptors (MC1R, MC3R); potent anti-inflammatory; inhibits NF-κB; reduces pro-inflammatory cytokines (TNF-α, IL-6).

Research areas

Inflammatory bowel disease (IBD); gut healing; skin inflammation; wound healing; anti-inflammatory therapy; often combined with BPC-157.

Regulatory / research status

Research / preclinical only

Half-life

Short (~minutes). Oral route viable for gut-targeted delivery.

Storage

Store sealed at room temperature, away from light and humidity.

Reported side effects

Very well-tolerated. Minimal known side effects.